BIIL 260 is a leukotriene B4 (BLT1) receptor antagonist and is the active metabolite of the prodrug BIIL 284. BIIL 260 is a novel anti-inflammatory. References: Birke FW, Meade CJ, Anderskewitz R, Speck GA, Jennewein HM. In vitro and in vivo pharmacological characterization of BIIL 284, a novel and potent leukotriene B(4) receptor antagonist. J Pharmacol Exp Ther. 2001 Apr;297(1):458-66. PubMed PMID: 11259574.

纯度：≥98%

CAS：204974-93-6